Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species

Oliver A. Cornely, Jose Antonio Vazquez, Jan De Waele, Robert Betts, Coleman Rotstein, Marcio Nucci, Peter G. Pappas, Andrew J. Ullmann

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Summary: The incidence of invasive candidiasis caused by non-albicans Candida (NAC) spp. is increasing. The aim of this analysis was to evaluate the efficacy of micafungin, caspofungin and liposomal amphotericin B in patients with invasive candidiasis and candidaemia caused by different Candida spp. This post hoc analysis used data obtained from two randomised phase III trials was conducted to evaluate the efficacy and safety of micafungin vs. caspofungin and micafungin vs. liposomal amphotericin B. Treatment success, clinical response, mycological response and mortality were evaluated in patients infected with C. albicans and NAC spp. Treatment success rates in patients with either C. albicans or NAC infections were similar. Outcomes were similar for micafungin, caspofungin and liposomal amphotericin B. Candida albicans was the most prevalent pathogen recovered (41.0%), followed by C. tropicalis (17.9%), C. parapsilosis (14.4%), C. glabrata (10.4%), multiple Candida spp. (7.3%) and C. krusei (3.2%). Age, primary diagnosis (i.e. candidaemia or invasive candidiasis), previous corticosteroid therapy and Acute Physiology and Chronic Health Evaluation II score were identified as potential predictors of treatment success and mortality. Micafungin, caspofungin and liposomal amphotericin B exhibit favourable treatment response rates that are comparable for patients infected with different Candida spp.

Original languageEnglish (US)
Pages (from-to)79-89
Number of pages11
JournalMycoses
Volume57
Issue number2
DOIs
StatePublished - Feb 1 2014
Externally publishedYes

Fingerprint

Invasive Candidiasis
caspofungin
Candida
Candidemia
Therapeutics
APACHE
Mortality
Candida albicans
micafungin
Adrenal Cortex Hormones
Safety
liposomal amphotericin B
Incidence
Infection

Keywords

  • C. glabrata
  • C. parapsilosis
  • C. tropicalis
  • Candida albicans
  • Invasive candidiasis
  • Micafungin

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species. / Cornely, Oliver A.; Vazquez, Jose Antonio; De Waele, Jan; Betts, Robert; Rotstein, Coleman; Nucci, Marcio; Pappas, Peter G.; Ullmann, Andrew J.

In: Mycoses, Vol. 57, No. 2, 01.02.2014, p. 79-89.

Research output: Contribution to journalArticle

Cornely, Oliver A. ; Vazquez, Jose Antonio ; De Waele, Jan ; Betts, Robert ; Rotstein, Coleman ; Nucci, Marcio ; Pappas, Peter G. ; Ullmann, Andrew J. / Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species. In: Mycoses. 2014 ; Vol. 57, No. 2. pp. 79-89.
@article{b715e6af7907414fa9c7543f2a28beb4,
title = "Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species",
abstract = "Summary: The incidence of invasive candidiasis caused by non-albicans Candida (NAC) spp. is increasing. The aim of this analysis was to evaluate the efficacy of micafungin, caspofungin and liposomal amphotericin B in patients with invasive candidiasis and candidaemia caused by different Candida spp. This post hoc analysis used data obtained from two randomised phase III trials was conducted to evaluate the efficacy and safety of micafungin vs. caspofungin and micafungin vs. liposomal amphotericin B. Treatment success, clinical response, mycological response and mortality were evaluated in patients infected with C. albicans and NAC spp. Treatment success rates in patients with either C. albicans or NAC infections were similar. Outcomes were similar for micafungin, caspofungin and liposomal amphotericin B. Candida albicans was the most prevalent pathogen recovered (41.0{\%}), followed by C. tropicalis (17.9{\%}), C. parapsilosis (14.4{\%}), C. glabrata (10.4{\%}), multiple Candida spp. (7.3{\%}) and C. krusei (3.2{\%}). Age, primary diagnosis (i.e. candidaemia or invasive candidiasis), previous corticosteroid therapy and Acute Physiology and Chronic Health Evaluation II score were identified as potential predictors of treatment success and mortality. Micafungin, caspofungin and liposomal amphotericin B exhibit favourable treatment response rates that are comparable for patients infected with different Candida spp.",
keywords = "C. glabrata, C. parapsilosis, C. tropicalis, Candida albicans, Invasive candidiasis, Micafungin",
author = "Cornely, {Oliver A.} and Vazquez, {Jose Antonio} and {De Waele}, Jan and Robert Betts and Coleman Rotstein and Marcio Nucci and Pappas, {Peter G.} and Ullmann, {Andrew J.}",
year = "2014",
month = "2",
day = "1",
doi = "10.1111/myc.12104",
language = "English (US)",
volume = "57",
pages = "79--89",
journal = "Mycoses",
issn = "0933-7407",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species

AU - Cornely, Oliver A.

AU - Vazquez, Jose Antonio

AU - De Waele, Jan

AU - Betts, Robert

AU - Rotstein, Coleman

AU - Nucci, Marcio

AU - Pappas, Peter G.

AU - Ullmann, Andrew J.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Summary: The incidence of invasive candidiasis caused by non-albicans Candida (NAC) spp. is increasing. The aim of this analysis was to evaluate the efficacy of micafungin, caspofungin and liposomal amphotericin B in patients with invasive candidiasis and candidaemia caused by different Candida spp. This post hoc analysis used data obtained from two randomised phase III trials was conducted to evaluate the efficacy and safety of micafungin vs. caspofungin and micafungin vs. liposomal amphotericin B. Treatment success, clinical response, mycological response and mortality were evaluated in patients infected with C. albicans and NAC spp. Treatment success rates in patients with either C. albicans or NAC infections were similar. Outcomes were similar for micafungin, caspofungin and liposomal amphotericin B. Candida albicans was the most prevalent pathogen recovered (41.0%), followed by C. tropicalis (17.9%), C. parapsilosis (14.4%), C. glabrata (10.4%), multiple Candida spp. (7.3%) and C. krusei (3.2%). Age, primary diagnosis (i.e. candidaemia or invasive candidiasis), previous corticosteroid therapy and Acute Physiology and Chronic Health Evaluation II score were identified as potential predictors of treatment success and mortality. Micafungin, caspofungin and liposomal amphotericin B exhibit favourable treatment response rates that are comparable for patients infected with different Candida spp.

AB - Summary: The incidence of invasive candidiasis caused by non-albicans Candida (NAC) spp. is increasing. The aim of this analysis was to evaluate the efficacy of micafungin, caspofungin and liposomal amphotericin B in patients with invasive candidiasis and candidaemia caused by different Candida spp. This post hoc analysis used data obtained from two randomised phase III trials was conducted to evaluate the efficacy and safety of micafungin vs. caspofungin and micafungin vs. liposomal amphotericin B. Treatment success, clinical response, mycological response and mortality were evaluated in patients infected with C. albicans and NAC spp. Treatment success rates in patients with either C. albicans or NAC infections were similar. Outcomes were similar for micafungin, caspofungin and liposomal amphotericin B. Candida albicans was the most prevalent pathogen recovered (41.0%), followed by C. tropicalis (17.9%), C. parapsilosis (14.4%), C. glabrata (10.4%), multiple Candida spp. (7.3%) and C. krusei (3.2%). Age, primary diagnosis (i.e. candidaemia or invasive candidiasis), previous corticosteroid therapy and Acute Physiology and Chronic Health Evaluation II score were identified as potential predictors of treatment success and mortality. Micafungin, caspofungin and liposomal amphotericin B exhibit favourable treatment response rates that are comparable for patients infected with different Candida spp.

KW - C. glabrata

KW - C. parapsilosis

KW - C. tropicalis

KW - Candida albicans

KW - Invasive candidiasis

KW - Micafungin

UR - http://www.scopus.com/inward/record.url?scp=84892900191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892900191&partnerID=8YFLogxK

U2 - 10.1111/myc.12104

DO - 10.1111/myc.12104

M3 - Article

C2 - 23786573

AN - SCOPUS:84892900191

VL - 57

SP - 79

EP - 89

JO - Mycoses

JF - Mycoses

SN - 0933-7407

IS - 2

ER -